MedPath

Studies Investigating Co-morbidities Aggravating Heart Failure

Completed
Conditions
Heart Failure
Type 2 Diabetes Mellitus
Registration Number
NCT01872299
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

SICA-HF is a prospective, multicentre, multinational, longitudinal, pathophysiological evaluation study, which is being conducted in 11 centres across six countries. SICA-HF receives funding from the European commission's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 241558 (SICA-HF) and from the Russian Ministry of Science and Education within the file transfer protocol "R\&D in priority fields of the S\&T complex of Russia 2007-2012" under state contract number 02.527.11.0007. The aim of SICA-HF is to provide detailed characteristics of co-morbidities of heart failure at baseline and over time, particularly with regards to obesity, cachexia, and type 2 diabetes.

Detailed Description

SICA-HF, consisting of outstanding European heart failure clinicians and basic researchers, has accomplished to provide a common platform for the two different research teams. All partners of SICA-HF recruited more than 1462 patients with chronic heart failure, 199 patients with type 2 diabetes without heart failure, and 173 healthy control subjects. Thus, during the last year, a cumulative 91.4% of the target value was achieved for patients with chronic heart failure, 66.3% of the target value for diabetic controls, and 115.3% and thus over-achieving for healthy subjects. The data of all participating centers were collected and entered into the central database. As of this writing, 1469 of all chronic heart failure patients' visits, 255 of diabetic controls' visits, and 167 healthy controls' visits have been entered into the online database. In total, 171 patients have been reported to be deceased; the total number of hospitalizations is 2232.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1600
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.March 31, 2014
Secondary Outcome Measures
NameTimeMethod
Change in exercise capacity and cardiorespiratory reflex controlMarch 31, 2014

To describe patterns of exercise capacity and cardiorespiratory reflex control

Incidence and prevalence of sleep-disordered breathing and its impact on the clinical severity in patients with chronic heart failureMarch 31, 2014
Change of body composition and its changes over timeMarch 31, 2014

To analyse body composition and its changes over time in patients with chronic heart failure and type 2 diabetes, obesity or cachexia

Impact of impaired vascular reactivity on impaired skeletal muscle metabolic and functional capacity, including its underlying mechanismsMarch 31, 2014
Changes of metabolic status in patients with heart failure and type 2 diabetes, obesity and cachexiaMarch 31, 2014

To describe the interplay and metabolic signalling pathways between adipose tissue, skeletal muscle, the bone marrow and the heart in patients with heart

Trial Locations

Locations (11)

Silesian Centre for Heart Diseases

๐Ÿ‡ต๐Ÿ‡ฑ

Zabrze, Poland

Wroclaw, Medical University

๐Ÿ‡ต๐Ÿ‡ฑ

Wroclaw, Poland

Hannover Medical School

๐Ÿ‡ฉ๐Ÿ‡ช

Hannover, Germany

University Clinic of Respiratory and Allergic diseases Golnik

๐Ÿ‡ธ๐Ÿ‡ฎ

Golnik, Slovenia

Russian Cardiology Research and Production Complex

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

IRCCS San Raffaele

๐Ÿ‡ฎ๐Ÿ‡น

Rom, Italy

Lomonosov Moscow State University

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Moskow, Russian Federation

Almazov Federal Center for Heart, Blood & Endocrinology

๐Ÿ‡ท๐Ÿ‡บ

St. Petersburg, Russian Federation

Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences

๐Ÿ‡ท๐Ÿ‡บ

Tomsk, Russian Federation

Charitรฉ- University Medicine Berlin, Campus Virchow Klinikum

๐Ÿ‡ฉ๐Ÿ‡ช

Berlin, Germany

University of HULL

๐Ÿ‡ฌ๐Ÿ‡ง

Hull, United Kingdom

ยฉ Copyright 2025. All Rights Reserved by MedPath